Elizabeth M. Gore, MD

Publications

• Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy.

  (Chan E, Pugh SL, Simko JP, Feng F, Shipley WU, Lukka HR, Bahary JP, Pisansky TM, Zeitzer KL, Gore E, Efstathiou JA, Rosenthal SA, Balogh AG, Lovett RD, Wong A, Dess RT, McGinnis LS, Kuettel M, DeMora L, Sandler HM.) Prostate. 2025 Oct;85(14):1315-1322 PMID: 40686005 PMCID: PMC12366761 SCOPUS ID: 2-s2.0-105011074274 07/21/2025

• Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.

  (Armstrong AJ, Liu VYT, Selvaraju RR, Chen E, Simko JP, DeVries S, Sartor O, Sandler HM, Mohamad O, Huang HC, Griffin J, Yamashita R, Esteva A, Tran PT, Spratt DE, Carson JH, Peters C, Gore E, Lee SP, Monson JM, Augspurger ME, El-Gayed A, Rodgers JP, McKay R, Morgan T, Feng FY, Nguyen PL.) J Clin Oncol. 2025 Apr 16:JCO2400365 PMID: 40239134 PMCID: PMC12228211 SCOPUS ID: 2-s2.0-105004600350 04/16/2025

• Radiobiologically equivalent deformable dose mapping for re-irradiation planning: Implementation, robustness, and dosimetric benefits.

  (García-Alvarez JA, Paulson E, Kainz K, Puckett L, Shukla ME, Zhu F, Gore E, Tai A.) Radiother Oncol. 2025 Apr;205:110741 PMID: 39855600 SCOPUS ID: 2-s2.0-85216209940 01/25/2025

• 5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies.

  (Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalainen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L.) Commun Med (Lond). 2025 Mar 04;5(1):61 PMID: 40038525 PMCID: PMC11880319 SCOPUS ID: 2-s2.0-86000110322 03/05/2025

• Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377.

  (Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY.) Int J Radiat Oncol Biol Phys. 2024 Dec 01;120(5):1461 PMID: 39320298 PMCID: PMC11698260 SCOPUS ID: 2-s2.0-85204708740 09/25/2024

• 5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapies.

  (Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalanen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L.) medRxiv. 2024 Oct 17 PMID: 37904926 PMCID: PMC10615016 10/31/2023

• Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery.

  (Kachnic LA, Winter K, Suntharalingam M, Ilson D, Konski A, Lloyd S, McAvoy SA, Lad T, Olowokure OG, Samson P, Gore EM, Meyer JE, Videtic GMM, Clump DA, Raben A, Kayaleh O, Barker J Jr, Haddock MG, Hopkins JO, Bruner DW.) Qual Life Res. 2024 Oct;33(10):2833-2844 PMID: 39066879 PMCID: PMC11577575 SCOPUS ID: 2-s2.0-85200043165 07/28/2024

• Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202.

  (Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M 3rd, Tran PT, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA.) Eur Urol Focus. 2024 Mar;10(2):271-278 PMID: 38307806 PMCID: PMC11257781 SCOPUS ID: 2-s2.0-85184044805 02/03/2024

• High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab

  (Ellison C, Martens M, Alvarez Argote J, Benz S, Currey A, Johnstone C, Klawikowski S, Livingston K, Longo JM, Menon S, Ortiz de Choudens S, Puckett L, Retseck J, Shukla M, Thompson J, Gore E.) Jto Clinical and Research Reports. December 2024;5(12) SCOPUS ID: 2-s2.0-85207777055 12/01/2024

• The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.

  (Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, Welsh J, Gore EM, MacRae RM, Paulus R, Bradley JD.) Cancer Res Commun. 2023 Oct 11;3(10):2074-2081 PMID: 37728512 PMCID: PMC10566451 SCOPUS ID: 2-s2.0-85195206743 09/20/2023

• Development of a comprehensive cardiac atlas on a 1.5 Tesla Magnetic Resonance Linear Accelerator.

  (Schottstaedt AM, Paulson ES, Rubenstein JC, Chen X, Omari EA, Li XA, Schultz CJ, Puckett LL, Robinson CG, Alongi F, Gore EM, Hall WA.) Phys Imaging Radiat Oncol. 2023 Oct;28:100504 PMID: 38035207 PMCID: PMC10682663 11/30/2023

• Development of a comprehensive cardiac atlas on a 1.5 Tesla Magnetic Resonance Linear Accelerator

  (Schottstaedt AM, Paulson ES, Rubenstein JC, Chen X, Omari EA, Li XA, Schultz CJ, Puckett LL, Robinson CG, Alongi F, Gore EM, Hall WA.) Physics and Imaging in Radiation Oncology. October 2023;28 SCOPUS ID: 2-s2.0-85176356378 10/01/2023